These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 32459005)
1. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. Sølling AS; Harsløf T; Langdahl B J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005 [TBL] [Abstract][Full Text] [Related]
2. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. Sølling AS; Harsløf T; Langdahl B J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753 [TBL] [Abstract][Full Text] [Related]
3. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518 [TBL] [Abstract][Full Text] [Related]
4. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion? Grassi G; Ghielmetti A; Zampogna M; Chiodini I; Arosio M; Mantovani G; Eller-Vainicher C J Clin Endocrinol Metab; 2024 Sep; 109(10):e1817-e1826. PubMed ID: 38609157 [TBL] [Abstract][Full Text] [Related]
5. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study. Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061 [TBL] [Abstract][Full Text] [Related]
7. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237 [TBL] [Abstract][Full Text] [Related]
8. The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension. Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Tsai JN; Leder BZ J Bone Miner Res; 2023 Jan; 38(1):26-34. PubMed ID: 36333954 [TBL] [Abstract][Full Text] [Related]
9. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607 [TBL] [Abstract][Full Text] [Related]
10. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD Bone; 2020 Sep; 138():115478. PubMed ID: 32534221 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS). Kang T; Park SY; Lee SH; Park JH; Suh SW J Korean Med Sci; 2022 Apr; 37(13):e68. PubMed ID: 35380023 [TBL] [Abstract][Full Text] [Related]
12. Effects of bone remodeling agents following teriparatide treatment. Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794 [TBL] [Abstract][Full Text] [Related]
13. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007 [TBL] [Abstract][Full Text] [Related]
14. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study. Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320 [TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645 [TBL] [Abstract][Full Text] [Related]
16. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series. Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746 [TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis. Kamanda-Kosseh M; Shiau S; Agarwal S; Kondapalli A; Colon I; Kil N; Bucovsky M; Lappe JM; Stubby J; Shane E; Cohen A J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38605469 [TBL] [Abstract][Full Text] [Related]
18. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. Koldkjær Sølling AS; Harsløf T; Langdahl B Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367 [TBL] [Abstract][Full Text] [Related]
19. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440 [TBL] [Abstract][Full Text] [Related]
20. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. Horne AM; Mihov B; Reid IR Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]